

GLAXOSMITHKLINE PLC
Form 6-K
December 12, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 December 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status Chief Executive Officer
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£13.0199 9 (partnership shares)
£13.0199 9 (matching shares)

Aggregated information

- d) Aggregated volume 18 Ordinary Shares
Price £13.0199
- e) Date of the transaction 2017-12-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|------------------------------------|--|
| a) Name | Mr R G Connor |
| b) Position/status | President, Global Manufacturing & Supply |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- | | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- | | |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan. |
| c) Price(s) and volume(s) | Price(s) Volume(s)
£13.0199 9 (partnership shares)
£13.0199 9 (matching shares) |

Aggregated information

- | | |
|-----------------------------|------------------------------|
| d) Aggregated volume | 18 Ordinary Shares |
| Price | £13.0199 |
| e) Date of the transaction | 2017-12-11 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

- | | |
|---------|----------------|
| a) Name | Mr S Dingemans |
|---------|----------------|

b) Position/status Chief Financial Officer

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.0199	9 (partnership shares)
	£13.0199	9 (matching shares)

Aggregated information

d) Aggregated volume 18 Ordinary Shares
Price £13.0199

e) Date of the transaction 2017-12-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hiron

b) Position/status SVP, Global Ethics & Compliance

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s) Price(s) Volume(s)
£13.0199 9 (partnership shares)
£13.0199 9 (matching shares)

Aggregated information

- d) Aggregated volume 18 Ordinary Shares
Price £13.0199
- e) Date of the transaction 2017-12-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels
- b) Position/status President, Global Pharmaceuticals
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£13.0199	9 (partnership shares)
	£13.0199	9 (matching shares)

Aggregated information

d) Aggregated volume 18 Ordinary Shares
Price £13.0199

e) Date of the transaction 2017-12-11

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
	Price(s) Volume(s)
c) Price(s) and volume(s)	£13.0199 9 (partnership shares) £13.0199 9 (matching shares)
Aggregated information	
d) Aggregated volume Price	18 Ordinary Shares £13.0199
e) Date of the transaction	2017-12-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	
--	--

Ordinary shares of 25 pence each
('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £13.0199 | 9 (partnership shares) |
| £13.0199 | 9 (matching shares) |
- Aggregated information
- d) Aggregated volume 18 Ordinary Shares
Price £13.0199
- e) Date of the transaction 2017-12-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Acquisition of Ordinary Shares
under the Company's Share
Reward Plan.

Price(s) Volume(s)

- c) Price(s) and volume(s) £13.0199 10 (partnership shares)
£13.0199 10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares
Price £13.0199
- e) Date of the transaction 2017-12-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares
under the Company's Share
Reward Plan.

Price(s) Volume(s)

- c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£13.0199 9 (partnership shares)

£13.0199 9 (matching shares)

Aggregated information

- d) Aggregated volume 18 Ordinary Shares
Price £13.0199
- e) Date of the transaction 2017-12-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£13.0199 9 (partnership shares)
£13.0199 9 (matching shares)
- d) Aggregated information

Aggregated volume	18 Ordinary Shares
Price	£13.0199
e) Date of the transaction	2017-12-11
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: December 12, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc